Aurobindo Pharma Ltd’s consolidated net profit increased three fold at ₹417 crore in the third quarter ended December 31, 2013, compared with ₹92 crore in the year-ago period. The total revenue grew 36 per cent at ₹2,140 crore (₹1,570 crore).
The sales in the US had increased by 81 per cent at ₹931 crore and there was growth in other markets as well.
The company’s scrip gained 2.30 per cent to end at ₹493.35 on the BSE.